We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Stored Blood for Transfusion Is Practical After Heart Surgery

By LabMedica International staff writers
Posted on 01 Nov 2015
Patients often need transfusions of red blood cells to replace the blood they have lost during major surgeries, however, the question of whether stored blood is safe for heart surgery patients has had mixed answers.

Red blood cells (RBCs) or erythrocytes that transport oxygen throughout the body go through several changes while in storage, potentially decreasing their oxygen-carrying ability and until now, it has not been clear as to whether such changes affect patient outcome after receiving transfusions.

Clinical scientists at the Karolinska University Hospital (Stockholm, Sweden) identified all patients who underwent coronary artery bypass graft surgery, heart valve surgery, or both between 1997 and 2012. More...
Transfusion data were obtained from the nationwide register of blood transfusions database. Storage of RBCs was classified with discrete patient groups who had exclusively received blood stored less than 14 days, 14 to 27 days, or 28 to 42 days, and a mixed storage category for patients receiving blood of mixed age. Follow-up was completed on December 31, 2013.

Between 1997 and 2012, 47,071 patients were transfused in connection with cardiac surgery in nine Swedish hospitals. Women constituted 39.2% and the mean ±SD age was 70.0 ±9.7 years. Of these patients, 36.6% exclusively received RBCs stored less than 14 days; 26.8%, RBCs stored 14 to 27 days; 8.9%, RBCs stored 28 to 42 days; and 27.8%, RBCs of mixed age. Most clinical parameters were similar in the groups, although the less common blood groups such as AB and B, were more common with longer storage. Recipients of the freshest blood received more transfusions, 3.1 versus 2. No differences were observed for a range of comorbidities. After investigating patient outcomes, the team found that the use of stored blood units did not influence heart surgery patient outcomes.

Ulrik Sartipy, MD, PhD, the lead author of the study said, “This study is by far the largest investigation focusing on the issue of blood storage in this very sensitive patient group, and we find absolutely no hint of negative health effects associated with stored blood.” The study provides very firm reassurance that the current blood storage practices are safe. The study was published on October 20, 2015, in the Journal of the American Medical Association (JAMA).

Related Links:

Karolinska University Hospital



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.